Background: Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway-targeted immunotherapy is becoming standard practice in the management of lung cancer. The expression of PD-L1protein is expected to apply to evaluate the prognosis or to predict the response to PD-1-blocking antibodies. The immunohistochemistry(IHC) assay forPD-L1, 22C3 pharmDx, has revealed that about30% of all non-small cell lung cancer (NSCLCs) express the PD-L1 with a high level. The association between PD-L1 positivity and the clinicopathological features in lung adenocarcinoma (ADC) remains unclear, however. Method: We retrospectively evaluated the PD-L1 expression in the surgically resected tumor tissues by IHC with the 22C3 assay, from 233 primary lung ADC patients. The PD-L1 tumor proportion score (TPS) was calculated as the percentage of at least 100 viable tumor cells with complete or partial membrane staining. TPS was reported in three categories (no expression, <1%; low expression, 1-49%; and high expression, 50%). Result: Of the 233 cases analyzed, the median age was 60 (range, 34-82 years), 149 (63.9%) patients were female, 167 (71.7%) patients were never-smokers, and 55 (23.6%) patients had stage Ⅲ (50) and Ⅳ (5) disease. Among them, 139 (59.7%) patients had activating EGFR mutations, and 23 (9.9%) patients were KRAS mutant. Proportions in each PD-L1 TPS category were: <1%, 63.9%(149/233); 1-49%, 23.6%(55/233); 50%, 12.5%(29/233). Wilcoxon rank sum test(Mann-Whitney U test) revealed that PD-L1 positivity had negative correlation with patient age (p ¼ 0.027), and positive correlation with male (p ¼ 0.001), smoker (p ¼ 0.007), advanced stage (p < 0.001). EGFR-mutated tumors (n¼ 139) demonstrated lower rates of PD-L1 expression [TPS <1% (72.7%); 1-49% (22.3%); 50% (5.0%); P<0.001];meanwhile, KRAS-mutated tumors (n¼ 23) showed higher rates of PD-L1 expression [TPS <1% (43.5%); 1-49% (30.4%); 50% (26.1%); P<0.001]. Conclusion: This investigation shows that in primary lung adenocarcinoma the PD-L1 expression was significantly associated with younger age, male, smokers, high stage disease, EGFR wild-type and KRAS mutant. Therefore, it is rational to choose a different checkpoint inhibitor according to the driver gene mutation status and to combine targeted therapies and anti-PD-L1 agents.
Background: Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway-targeted immunotherapy is becoming standard practice in the management of lung cancer. The expression of PD-L1protein is expected to apply to evaluate the prognosis or to predict the response to PD-1-blocking antibodies. The immunohistochemistry(IHC) assay forPD-L1, 22C3 pharmDx, has revealed that about30% of all non-small cell lung cancer (NSCLCs) express the PD-L1 with a high level. The association between PD-L1 positivity and the clinicopathological features in lung adenocarcinoma (ADC) remains unclear, however. Method: We retrospectively evaluated the PD-L1 expression in the surgically resected tumor tissues by IHC with the 22C3 assay, from 233 primary lung ADC patients. The PD-L1 tumor proportion score (TPS) was calculated as the percentage of at least 100 viable tumor cells with complete or partial membrane staining. TPS was reported in three categories (no expression, <1%; low expression, 1-49%; and high expression, 50%). Result: Of the 233 cases analyzed, the median age was 60 (range, 34-82 years), 149 (63.9%) patients were female, 167 (71.7%) patients were never-smokers, and 55 (23.6%) patients had stage Ⅲ (50) and Ⅳ (5) disease. Among them, 139 (59.7%) patients had activating EGFR mutations, and 23 (9.9%) patients were KRAS mutant. Proportions in each PD-L1 TPS category were: <1%, 63.9%(149/233); 1-49%, 23.6%(55/233); 50%, 12.5%(29/233). Wilcoxon rank sum test(Mann-Whitney U test) revealed that PD-L1 positivity had negative correlation with patient age (p ¼ 0.027), and positive correlation with male (p ¼ 0.001), smoker (p ¼ 0.007), advanced stage (p < 0.001). EGFR-mutated tumors (n¼ 139) demonstrated lower rates of PD-L1 expression [TPS <1% (72.7%); 1-49% (22.3%); 50% (5.0%); P<0.001];meanwhile, KRAS-mutated tumors (n¼ 23) showed higher rates of PD-L1 expression [TPS <1% (43.5%); 1-49% (30.4%); 50% (26.1%); P<0.001]. Conclusion: This investigation shows that in primary lung adenocarcinoma the PD-L1 expression was significantly associated with younger age, male, smokers, high stage disease, EGFR wild-type and KRAS mutant. Therefore, it is rational to choose a different checkpoint inhibitor according to the driver gene mutation status and to combine targeted therapies and anti-PD-L1 agents. Keywords: PD-L1, Adenocarcinoma, lung Background: Four PD-L1 antibodies have been utilized in NSCLC clinical trials, with an analytical comparison demonstrating a high level of concordance between the percentage of PD-L1estained tumor cells with three of these antibodies (22C3, 22C3, 28-8, and SP263), but not a fourth, SP-142 (Hirsch et al, JTO 2017) . This finding led us to evaluate the relationship between the percentage of PD-L1estained tumor cells with 22C3 and SP-142, as well as the association between the PD-L1 levels identified by each antibody and clinical outcomes in 28 NSCLC patients treated on KEYNOTE-001. Method: We performed a retrospective analysis of 28 NSCLC patients treated with pembrolizumab on the KEYNOTE-001 trial at UCLA (23pts) or MSKCC (5pts) with data cutoff 12/2017. Patients had PD-L1estained tumor cell levels assessed by both the 22C3 antibody (Dako), via central evaluation as previously described (Garon et al, NEJM 2015) and the SP-142 antibody (Spring Bioscience) at UCLA in accordance with established methods (Zaretsky et al, NEJM 2016). Survival curves for PFS and OS were estimated using the Kaplan-Meier method and formally compared between groups using the log-rank test. The association between PD-L1estained tumor cell levels identified by the two antibodies was assessed using the Pearson correlation coefficient. Result: In 61% (17/28) of patients, PD-L1 levels were grouped similarly (either <1%, 1-49%, or >50%) by both antibodies. Specifically, compared to 22C3 staining, SP-142 led to the same grouping for 63% (5/8) pts with >50% staining, 85% (11/ 13) pts with 1-49% staining, and 14% (1/7) pts w <1% staining. Evaluating the relationship between PD-L1 grouping and clinical outcomes via the SP-142 antibody revealed improved PFS and OS in pts with higher PD-L1 expression levels, while the 22C3 antibody predicted for improved PFS in these patients, but not improved OS [SP142 (PFS,OS): (p¼0.0039, p¼0.0425)][22C3 (PFS,OS): p¼0.0121, p¼0.1222). The PD-L1 results from the SP-142 and 22C3 antibodies were strongly associated (r ¼0.58, p¼0.001). Conclusion: The PD-L1estained tumor cell levels in the majority of patients evaluated were similarly grouped into one of three categories (<1%, 1-49%, or >50%) by both 22C3 and SP142. This analysis is limited by small patient number, but suggests that the number of PD-L1estained tumor cells identified by each antibody is similar and a higher PD-L1 level identified by either antibody predicts for improved clinical outcomes with pembrolizumab. Keywords: PD-L1, pembrolizumab, KEYNOTE-001, Background: The SP263 (Ventana Benchmark) antibody as a predictive immunohistochemical marker for pembrolizumab therapy provides an avenue for local testing. Pathologists without access to the Dako Autostainer Link 48 platform (certified for the Dako 22C3 antibody) have been restricted to referrals at external departments, resulting in an increased turnaround time. Here we report the results of our local verification of SP263. Method: Specimens previously assessed for 22C3 PD-L1 expression at either Royal Liverpool Hospital or Queen Elizabeth Hospital Birmingham were selected from the archives of Wythenshawe Hospital. Cases with less than 100 viable residual tumour cells were excluded. The same tumour block was selected for staining with the Roche SP263 clone and specimens were assessed for tumour proportion score (TPS), immune cell proportion and staining intensity. Assays were reported as disagreeing if a differing TPS changed the therapeutic cut-off ranges. Result: Expression levels of
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